Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Berlin Registry of Right Heart Interventions

NCT04570163 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2020-06-16
Last updated
2026-03-19

Condition(s) studied

Tricuspid RegurgitationPulmonary Regurgitation

Investigational drug(s) / intervention(s)

Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)

Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband): Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).

Study summary

The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.

Eligibility

Sex
ALL
Min age
18 Years
Max age
120 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with planned or recent valve interventions of the right heart (tricuspid regurgitation/ stenosis, pulmonary regurgitation/ stenosis) * \>18 years * Written, documented consent Exclusion Criteria: * Patients in care or unable to consent * Patients who are unable to comply with follow-up examinations * Patients who are detained in an institution

Primary outcome measure(s)

  • Overall mortality — 2 months after intervention
    Number of deceased participants after 2 months after intervention
  • Cardiovascular mortality — 2 months after intervention
    Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)
  • Unscheduled hospitalization for heart failure progression — 2 months after intervention
    Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention

Trial sites (1)

FacilityCityRegionStatus
Charité - Universitätsmedizin Berlin Berlin Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04570163 on ClinicalTrials.gov ↗ ← All trials in Germany